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OBJECTIVES: Bankruptcy may be a particular concern for cancer patients. Costs
from treatment and supportive care, along with non-medical costs such as lost
income, can be financially devastating. We estimated the incidence of bankruptcy
following cancer diagnosis using linked cases from the Washington SEER registry
withWestern District ofWashington bankruptcy court records.METHODS: Cancer
cases (age20) were identified for 1995-2009. Our analyseswere limited to patients
reporting their first primary cancer, excluding cancers in situ or diagnosed at time
of death. To determine the proportion of cancer cases reporting personal bank-
ruptcy (Chapter 7 or 13) following cancer diagnosis, we generated cumulative inci-
dence (CI) of bankruptcy, to allow for the competing risk of death.We calculated CI
using Gray’s method to compare bankruptcies among different cancers. RESULTS:
There were N231,799 cancer cases; after a mean follow-up of 4.3(sd4.1) years,
N4805 (2.1%) had filed for bankruptcy after cancer diagnosis. Average age at di-
agnosis of filers was 52.8(sd13.6) years and 55% were female compared to
63.9(sd14.6) years and 49% female for all cancer cases (p0.0001 for both compar-
isons). Mean andmedian time to bankruptcy was 3.3 and 2.5 years, respectively. At
1, 2 and 3 years following diagnosis, the proportion of bankruptcies filed was 23%,
41%, and 56%, respectively. By 3 years, the incidence of bankruptcy was 1.3%.
Thyroid cancer had the highest CI at 3 years (2.7%), followed by uterine (1.7%),
melanoma (1.6%), breast (1.6%), leukemia/lymphoma (1.4%), colorectal (1.2%), lung
(1%) and prostate (0.9%); the CI for all other cancers was 1.3%. The overall CI of
bankruptcy was 3.3%. CONCLUSIONS: Two in 100 patients file for bankruptcy fol-
lowing a cancer diagnosis. Thyroid and uterine cancer have the highest incidence
of bankruptcy. Factors associated with bankruptcy following cancer are yet to be
determined.
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OBJECTIVES: Patients treated for neuroendocrine tumors and acromegaly have to
be periodically injected with a long-acting somatostatin analog (SSA). This study
aimed at evaluating the economic implications of using a new pre-filled device for
Somatuline Autogel/Depot versus Sandostatin LAR. The study was performed in
three European countries and the US. METHODS: A quantitative study was per-
formed in France, Germany, the UK and the US, including 77 nurses. The majority
of nurses were from hospital wards, specialized in endocrinology and oncology.
The number of SSA patients per nurse was at least 3 per year. Time spent for each
injection and number of clogging episodes was recorded per nurse and per type of
injection (Somatuline new device or LAR). Cost of successful injection was calcu-
lated per patient / per nurse using retail costs for the 4 countries. RESULTS: With
LAR, 2 clogging incidents were reported. This led to an average of 79 injections for
LAR vs. 77 for Somatuline new device. The calculated cost per successful injection
for the 4 countries pooled together was in Euro: 1’603 and 1’628 respectively for
Somatuline new device and LAR. The incremental cost between the 2 treatments
was EUR 25 per injection. Assuming an 85% compliance, this translated up to EUR
255 per patient per year. When considering only the 3 European countries, the
annual difference was EUR 724. CONCLUSIONS: The usage of a new pre-filled So-
matuline device for the injection of SSA could lead to substantial savings for hos-
pitals and health-care payers. Due to the differences in retail prices across coun-
tries, these savings could potentially be even more significant in Europe.
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OBJECTIVES: Heterogeneity of treatment effects and variation in expenditures
across subgroups impact the cost-effectiveness of health care interventions. This
study investigates the variation in costs, effects, and incremental cost-effective-
ness ratios (ICERs) associatedwith chemotherapy receipt in elderlymetastatic (M1)
prostate cancer (PC) patients across race/ethnicity subgroups (Non-Hispanic
Whites, Non-Hispanic Blacks, Others). METHODS: We examined patients aged 66
or older identified using linked Surveillance, Epidemiology and End Results (SEER)-
Medicare data, who were diagnosed with M1 PC between 2000 and 2005. Cost data
based on Medicare reimbursements were available for 36 months after diagnosis.
Mean costs and effects (life-years gained, LYG) were adjusted for censoring using
inverse probability weighting. The baseline scenario examined PC-specificmedical
costs up to 24 months and required patients to be alive for at least 3 months after
diagnosis. Sensitivity analysis considered sampling uncertainty, selection into
treatment, and adjustments to initial model assumptions. RESULTS:We identified
3,888 M1 PC patients, of which 24% (N930) received chemotherapy (mostly do-
cetaxel andmitoxantrone). Twenty percent of observationswere censored. The full
sample ICER was $99,146 per LYG (95% CI: $75,041-$130,194). Compared to Whites
($107,095; CI: $78,391-$148,272), ICER point estimates were lower for Blacks
($59,887; CI: $22,860-$121,509) and higher for Others ($123,909; CI: $37,782-
$366,376). We also observed substantial variation across racial subgroups in the
probability of chemotherapy being cost-effective given various willingness-to-pay
thresholds per LYG. Results were similar in sensitivity analysis. CONCLUSIONS:
Chemotherapy use in elderly M1 PC patients is associated with an ICER of $99,146
per LYG in our sample. Subgroup analysis revealed racial heterogeneity in ICER
point estimates and considerable statistical uncertainty. In order to generate a
reliable evidence base for personalized medicine, efforts to increase the represen-
tation ofminorities in clinical trials, registries, and other health care datasets need
to continue.
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OBJECTIVES: Renal cell carcinoma (RCC) is the most common primary renal ma-
lignant neoplasm in adults. It accounts for approximately 90% of renal tumors and
2% of all adult malignancies. The purpose of this study was to estimate the cost-
effectiveness of temsirolimus versus interferon- for patients treated as first line
with metastatic renal-cell carcinoma and poor prognosis from an institutional
perspective. METHODS: A three-state Markov model was performed to estimate
health and economic consequences during a time horizon of 12 months (six–week
cycles). Effectiveness measures were: overall survival, progression-free survival
(months), and quality adjusted life years gained (QALYs). Drug safety was also
assessed (grade 3-4 adverse events-AE). Transition probabilities were obtained
from a meta-analysis collecting international published literature data. Doses of
comparators were: temsirolimus (25mg/week) and interferon- (41,380,000 IU/
week). Resource use was obtained from Social Security Mexican Institute hospital
records (n154). Costs were extracted from institutional sources and include: hos-
pitalization, drugs, medical procedures, laboratory tests and adverse events man-
agement. Probabilistic sensitivity analyses were performed and acceptability
curves were constructed. RESULTS: Temsilorimus overall survival resulted in 10.9
months (CI 95% 10.63 – 11.17) and interferon- achieved 7.3 months (7.09 – 7.51)
(p0.05). For progression-free survival, temsirolimus estimation was 5.5 months
(5.36 – 5.64) and interferon- exhibited 3.1 months (3.01 – 3.19) (p0.05). Lastly,
temsirolimus raised QALYs in 0.74 (0.72 – 0.76), (p0.05), and diminished grade 3-4
hematologic AE in9.59% (9.35% -9.83%), (p0.05). Incremental cost-effective-
ness ratio (ICER) for overall survival and progression-free survival for temsirolimus
against interferon- were US$4,839 [US$4,718-US$4,961] and US$7,259 [US$7,077-
US$7,441], respectively. The ICER using QALYs resulted in US$23,458 [US$22,869-
US$24,046]. Probabilistic sensitivity analyses showed that results were robust.
CONCLUSIONS: Regarding overall survival, progression–free survival and QALYs
temsirolimus represents a cost-effective therapy in Mexican patients who suffer
metastatic renal-cell carcinoma and poor prognosis.
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OBJECTIVES: National guidelines recommend a 21-gene Recurrence Score (RS) to
aid in adjuvant treatment decision in estrogen-receptor-positive, node-negative
early stage breast cancer (ER, LN- ESBC) patients. To assess the economic impli-
cation of the assay in community practices from the perspective of an US payer.
METHODS: Analysis of 952 women with ESBC enrolled with Humana, Inc. (Louis-
ville, KY) tested with the 21-gene RS between June, 2006 and June, 2010. The pro-
portion of women classified by the assay by RS risk categories, utilization and costs
of chemotherapy regimens, and supportive care, and costs of adverse events were
obtained fromHumana.We adapted a validatedMarkovmodel to compute the cost
implications of RS for a representative patient. The probability of risk of recurrence,
chemotherapy benefits and decision impact of RS were derived from published
studies. RESULTS: 255 patients within the tested population received adjuvant
chemotherapy. Adjuvant chemotherapywas administered to 10% of women at low
risk, 36% of women at intermediate risk, and 72% of women at high risk of recur-
rence. Based on a meta-analysis in the reduction of chemotherapy after RS, the
model estimated an average per patient test saving of $1,115. The immediate direct
savings for chemotherapy drug, supportive care, and management of adverse
events were $1,897, $2,593, $475, respectively. Prevention of recurrence through
appropriate treatment of high-risk patients resulted in additional saving of $126.
CONCLUSIONS: The adoption of the 21-gene RS lead to targeted management of
women with ER, LN- ESBC, and consequently save direct medical costs.
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OBJECTIVES: Approximately 60% of breast cancer cases are a type sensitive to
hormones. Tamoxifen is the most widely used treatment of hormone-dependent
breast cancer. The pharmacological activity of tamoxifen is dependent on its con-
version by the hepatic drug–metabolizing enzyme CYP2D6. Patients with reduced
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